Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Medical Research！丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future
🌟Chinese Medical Research！🌟
丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future
GPRC5D, Multiple Myeloma
🌷”#JournalofClinicalOncology” 🌷
brings hope for patients with relapsed/refractory #MultipleMyeloma (R/R MM) through a groundbreaking CAR-T cell therapy targeting a “new bull’s eye”.
🌻Led by Professor Xu Kailin’s team
from Affiliated Hospital of Xuzhou Medical University, this study delved into the efficacy and safety of CAR-T cell therapy targeting GPRC5D in R/R MM patients.
🌼GPRC5D,
a member of the G-protein coupled receptor family, showed significantly higher expression on malignant and normal plasma cells in bone marrow compared to peripheral blood cells, laying the groundwork for it to be a prime target for CAR-T cell therapy.
🌺In this study involving 33 R/R MM patients, all received CAR-T cell therapy targeting GPRC5D, with remarkable results! The overall response rate hit 91%(ORR), including a strict complete response rate of 33%. Notably, patients previously treated with BCMA-targeted CAR-T therapy also saw partial or better responses.
🪷Despite these strides in efficacy, safety remains a key concern. The most common adverse events included hematologic toxicities like neutropenia, anemia, and thrombocytopenia, along with cytokine release syndrome and neurotoxicity.
This study’s findings shine a beacon of hope for R/R MM patients. The GPRC5D-targeted CAR-T cell therapy displays promising clinical efficacy and manageable safety, offering a potential alternative for those progressing after BCMA therapy or developing resistance.
🥀This breakthrough not only expands treatment options for MM patients but also sets a new course for the future development of CAR-T cell therapy.
🌹To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp+8613717959070
doctor.huang@globecancer.com
#CARTCellTherapy #MultipleMyeloma #ClinicalResearch #HopeForTheFuture #MedicalBreakthroughs #newhope #BCMA #cart #gprc5d #cartcell #celltherapy